Asia Pacific Viscosupplementation Market Size & Outlook
Asia Pacific viscosupplementation market, 2018-2030 (US$M)
Related Markets
Asia Pacific viscosupplementation market highlights
- The Asia Pacific viscosupplementation market generated a revenue of USD 2,201.9 million in 2023.
- The market is expected to grow at a CAGR of 9.9% from 2024 to 2030.
- In terms of segment, single injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Australia is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 2,201.9 million |
| Market revenue in 2030 | USD 4,260.9 million |
| Growth rate | 9.9% (CAGR from 2023 to 2030) |
| Largest segment | Single injection |
| Fastest growing segment | Single Injection |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 45.7% of the global viscosupplementation market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 1,284.7 million by 2030.
Single injection was the largest segment with a revenue share of 43.05% in 2023. Horizon Databook has segmented the Asia Pacific viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
Improvements in healthcare facilities due to economic development witnessed in the emerging countries, such as China, Japan, South Korea, and India, have projected the Asia Pacific region as the most potentially lucrative market. Japan was the largest Asia Pacific market in 2016.
High awareness levels about single-injection treatment of osteoarthritis is expected to drive regional market. Owing to a greater demand for cost-effective products in the Asia Pacific region, the multiple-injection treatment cycle exhibited higher demand as compared to the single-injection counterpart.
According to National Health Portal of India, osteoarthritis is the second most common joint disease in India with 22% to 39% of the prevalence rate. In addition, 45% of women in India aged 65 years or above report symptoms of osteoarthritis.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific viscosupplementation market size, by country, 2018-2030 (US$M)
Asia Pacific Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
